Peripheral Neuropathies of Rheumatologic Disease and Gluten-Related Disorders

Abstract

Peripheral nervous system disease is a common and often debilitating feature of many systemic rheumatologic disorders. Such involvement takes many forms, reflecting the variety of underlying pathophysiology, though most patients present with painful multifocal neuropathy (usually vasculitic) or a distal sensory more than motor peripheral neuropathy (sometimes vasculitic and nearly always axonal). The presence of peripheral nervous system involvement is often an early signal of the generalization of inflammatory disease in blood vessels or extravascular tissues, though peripheral neuropathy is not itself an independent predictor of mortality. Nonetheless, progressive multifocal neuropathy, motor neuropathy, small fiber neuropathy, and sensory neuronopathy should be treated early and aggressively with immunosuppression (or the gluten-free diet in appropriate situations) to limit morbidity. Given the rapidly evolving therapeutic landscape, partnership with a rheumatologist is essential. Treatment is usually sustained for 1 to 2 years, and remission is possible in many cases within 6 to 12 months, with variable rates of relapse and treatment resistance. Patients should be meticulously monitored for relapse with serial laboratory testing, electrodiagnostic studies, and clinical examination. Functional rating scores, such as the neuropathy impairment scale and the total neuropathy score are useful for longitudinal assessment.

Keywords

vasculitis - rheumatologic - neuropathy - celiac - fibromyalgia

• References

• 1 Wolf J, Schmitt V, Palm F, Grau AJ, Bergner R. Peripheral neuropathy as initial manifestation of primary systemic vasculitides. J Neurol 2013; 260 (4) 1061-1070
• 2 Jennette JC, Falk RJ, Andrassy K , et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37 (2) 187-192
• 3 Jennette JC, Falk RJ, Bacon PA , et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65 (1) 1-11
• 4 Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33 (1) 4-9
• 5 Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999; 53 (9) 2113-2121
• 6 Collins MP, Kissel JT. Neuropathies with systemic vasculitis. In: Dyck PJ, Thomas PK, , eds. Peripheral Neuropathy. Vol 2. 4th ed. Philadelphia: Saunders; 2005: 2335-2404
• 7 Puéchal X, Said G, Hilliquin P , et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995; 38 (11) 1618-1629
• 8 Suppiah R, Hadden RD, Batra R , et al; European Vasculitis Study Group. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2011; 50 (12) 2214-2222
• 9 Samson M, Puéchal X, Devilliers H , et al; French Vasculitis Study Group (FVSG). Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev 2014; 13 (2) 197-205
• 10 Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P ; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90 (1) 19-27
• 11 Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26 (5) (Suppl. 51) S94-S104
• 12 Guillevin L, Lhote F, Gayraud M , et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75 (1) 17-28
• 13 de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58 (8) 1215-1221
• 14 Mori A, Hira K, Hatano T , et al. Bilateral facial nerve palsy due to otitis media associated with myeloperoxidase-antineutrophil cytoplasmic antibody. Am J Med Sci 2013; 346 (3) 240-243
• 15 Holding S, Fisher VJ, Abuzakouk M. Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis. Ann Clin Biochem 2014; ; [Epub ahead of print]
• 16 Chalk CH, Homburger HA, Dyck PJ. Anti-neutrophil cytoplasmic antibodies in vasculitis peripheral neuropathy. Neurology 1993; 43 (9) 1826-1827
• 17 Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?. Ann Rheum Dis 2013; 72 (8) 1273-1279
• 18 Lionaki S, Blyth ER, Hogan SL , et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64 (10) 3452-3462
• 19 Falk RJ, Gross WL, Guillevin L , et al; American College of Rheumatology; American Society of Nephrology; European League Against Rheumatism. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63 (4) 863-864
• 20 Terrier B, Saadoun D, Sène D , et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009; 68 (10) 1564-1571
• 21 Sandbrink F, Klion AD, Floeter MK. “Pseudo-conduction block” in a patient with vasculitic neuropathy. Electromyogr Clin Neurophysiol 2001; 41 (4) 195-202
• 22 Vital C, Vital A, Canron MH , et al. Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases. J Peripher Nerv Syst 2006; 11 (1) 20-29
• 23 Said G, Lacroix-Ciaudo C, Fujimura H, Blas C, Faux N. The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. Ann Neurol 1988; 23 (5) 461-465
• 24 Vital A, Vital C. Polyarteritis nodosa and peripheral neuropathy. Ultrastructural study of 13 cases. Acta Neuropathol 1985; 67 (1-2) 136-141
• 25 Sugiura M, Koike H, Iijima M , et al. Clinicopathologic features of nonsystemic vasculitic neuropathy and microscopic polyangiitis-associated neuropathy: a comparative study. J Neurol Sci 2006; 241 (1-2) 31-37
• 26 Dyck PJ, Conn DL, Okazaki H. Necrotizing angiopathic neuropathy. Three-dimensional morphology of fiber degeneration related to sites of occluded vessels. Mayo Clin Proc 1972; 47 (7) 461-475
• 27 Collins MP, Dyck PJ, Gronseth GS , et al. Peripheral Nerve Society. Peripheral Nerve Society guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 2010; 15 (3) 176-184
• 28 Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant 1991; 6 (8) 531-535
• 29 Haubitz M, Schellong S, Göbel U , et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41 (10) 1835-1844
• 30 Harper L, Morgan MD, Walsh M , et al. EUVAS investigators. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71 (6) 955-960
• 31 de Groot K, Harper L, Jayne DR , et al. EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150 (10) 670-680
• 32 Stone JH, Merkel PA, Spiera R , et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (3) 221-232
• 33 Jones RB, Tervaert JW, Hauser T , et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363 (3) 211-220
• 34 Specks U, Merkel PA, Seo P , et al; RAVE-ITN Research Group. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369 (5) 417-427
• 35 Pendergraft III WF, Cortazar FB, Wenger J , et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 2014; 9 (4) 736-744
• 36 Hiemstra TF, Walsh M, Mahr A , et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304 (21) 2381-2388
• 37 Reinhold-Keller E, de Groot K. Use of methotrexate in ANCA-associated vasculitides. Clin Exp Rheumatol 2010; 28 (5) (Suppl. 61) S178-S182
• 38 Silva-Fernández L, Loza E, Martínez-Taboada VM , et al; Systemic Autoimmune Diseases Study Group of the Spanish Society for Rheumatology (EAS-SER). Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum 2014; 43 (4) 542-557
• 39 Bremer JP, Ullrich S, Laudien M, Gross WL, Lamprecht P. Methotrexate plus leflunomide for the treatment of relapsingWegener's granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol 2010; 28 (1) (Suppl. 57) 67-71
• 40 Hazlewood GS, Metzler C, Tomlinson GA , et al. Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: A systematic review and network meta-analysis. Joint Bone Spine 2014; 81 (4) 337-341
• 41 Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998; 13 (8) 2074-2076
• 42 Tuso P, Moudgil A, Hay J , et al. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 1992; 20 (5) 504-508
• 43 de Joode AA, Sanders JS, Smid WM, Stegeman CA. Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: Single-center results of stepwise escalation of immunosuppression. J Clin Apher 2014; ; [Epub ahead of print]
• 44 Wang CC, Shiang JC, Tsai MK , et al. Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative microscopic polyangiitis. Clin Rheumatol 2009; 28 (12) 1457-1460
• 45 Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995; 45 (6) 1115-1121
• 46 Cornblath DR, Chaudhry V, Carter K , et al. Total neuropathy score: validation and reliability study. Neurology 1999; 53 (8) 1660-1664
• 47 Li ZY, Chang DY, Zhao MH, Chen M. Predictors of treatment resistance and relapse in ANCA-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheum (Munch) 2014; 66 (7) 1920-1926
• 48 Handa R, Wali JP, Gupta SD , et al. Classical polyarteritis nodosa and microscopic polyangiitis—a clinicopathologic study. J Assoc Physicians India 2001; 49: 314-319
• 49 Pagnoux C, Seror R, Henegar C , et al. French Vasculitis Study Group. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62 (2) 616-626
• 50 Guillevin L, Mahr A, Callard P , et al. French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84 (5) 313-322
• 51 Sassi SB, Ghorbel IB, Mizouni H, Houman MH, Hentati F. Microscopic polyangiitis presenting with peripheral and central neurological manifestations. Neurol Sci 2011; 32 (4) 727-729
• 52 Villiger PM, Guillevin L. Microscopic polyangiitis: clinical presentation. Autoimmun Rev 2010; 9 (12) 812-819
• 53 Wolf J, Bergner R, Mutallib S, Buggle F, Grau AJ. Neurologic complications of Churg-Strauss syndrome—a prospective monocentric study. Eur J Neurol 2010; 17 (4) 582-588
• 54 Cattaneo L, Chierici E, Pavone L , et al. Peripheral neuropathy in Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry 2007; 78 (10) 1119-1123
• 55 Hattori N, Mori K, Misu K, Koike H, Ichimura M, Sobue G. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol 2002; 29 (7) 1408-1414
• 56 Holle JU, Gross WL, Holl-Ulrich K , et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?. Ann Rheum Dis 2010; 69 (11) 1934-1939
• 57 Schmidt WA, Moll A, Seifert A, Schicke B, Gromnica-Ihle E, Krause A. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford) 2008; 47 (9) 1406-1408
• 58 Caselli RJ, Daube JR, Hunder GG, Whisnant JP. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 1988; 38 (5) 685-689
• 59 Chan WM, Liu DT, Chan AY, Lai CH, Choi PC, Lam DS. ANCA-associated giant cell arteritis presenting with mononeuritis multiplex and central retinal artery occlusion: a case report. Rheumatology (Oxford) 2004; 43 (4) 529-531
• 60 Chowdhry IA, Sinha J, Barland P. Brachial plexopathy as a presenting symptom of giant cell arteritis. J Rheumatol 2002; 29 (12) 2653-2657
• 61 Rivest D, Brunet D, Desbiens R, Bouchard JP. C-5 radiculopathy as a manifestation of giant cell arteritis. Neurology 1995; 45 (6) 1222-1224
• 62 Soubrier M, Dubost JJ, Tournadre A, Deffond D, Clavelou P, Ristori JM. Cervical radiculopathy as a manifestation of giant cell arteritis. Joint Bone Spine 2002; 69 (3) 316-318
• 63 Dennis II RH, Ransome JR. Giant cell arteritis presenting as a carpal tunnel syndrome. J Natl Med Assoc 1996; 88 (8) 524-525
• 64 González-Gay MA, García-Porrúa C, Brañas F, Alba-Losada J. Giant cell arteritis presenting as occipital neuralgia. Clin Exp Rheumatol 2001; 19 (4) 479
• 65 Bridges AJ, Porter J, England D. Lower extremity peripheral neuropathy and ischemic ulcers associated with giant cell arteritis. J Rheumatol 1989; 16 (10) 1366-1369
• 66 Dierckx RA, Ebinger G, Herregodts P , et al. Recurrent brachial plexus neuropathy and giant cell arteritis. Clin Neurol Neurosurg 1990; 92 (1) 71-74
• 67 Lacomis D, Giuliani MJ, Wasko MC, Oddis CV. Giant cell arteritis presenting with proximal weakness and skeletal muscle vasculitis. Muscle Nerve 1999; 22 (1) 142-144
• 68 García Gasalla M, Yebra Bango M, Vargas Núñez JA , et al. Giant cell arteritis associated with demyelinating polyradiculoneuropathy. Ann Rheum Dis 2001; 60 (8) 812-813
• 69 Biswas M, Chatterjee A, Ghosh SK, Dasgupta S, Ghosh K, Ganguly PK. Prevalence, types, clinical associations, and determinants of peripheral neuropathy in rheumatoid patients. Ann Indian Acad Neurol 2011; 14 (3) 194-197
• 70 Agarwal V, Singh R , Wiclaf, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol 2008; 27 (7) 841-844
• 71 Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford) 2014; 53 (5) 890-899
• 72 Albani G, Ravaglia S, Cavagna L, Caporali R, Montecucco C, Mauro A. Clinical and electrophysiological evaluation of peripheral neuropathy in rheumatoid arthritis. J Peripher Nerv Syst 2006; 11 (2) 174-175
• 73 Puéchal X. Incidence of vasculitis in rheumatoid arthritis: comment on the article by Turesson et al. Arthritis Rheum 2005; 52 (5) 1620 , author reply 1621
• 74 Lanzillo B, Pappone N, Crisci C, di Girolamo C, Massini R, Caruso G. Subclinical peripheral nerve involvement in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41 (7) 1196-1202
• 75 Bekkelund SI, Torbergsen T, Husby G, Mellgren SI. Myopathy and neuropathy in rheumatoid arthritis. A quantitative controlled electromyographic study. J Rheumatol 1999; 26 (11) 2348-2351
• 76 Muramatsu K, Tanaka H, Taguchi T. Peripheral neuropathies of the forearm and hand in rheumatoid arthritis: diagnosis and options for treatment. Rheumatol Int 2008; 28 (10) 951-957
• 77 McGuigan L, Burke D, Fleming A. Tarsal tunnel syndrome and peripheral neuropathy in rheumatoid disease. Ann Rheum Dis 1983; 42 (2) 128-131
• 78 Belcher HJ, Varma S, Schonauer F. Endoscopic carpal tunnel release in selected rheumatoid patients. J Hand Surg [Br] 2000; 25 (5) 451-452
• 79 Karadag O, Kalyoncu U, Akdogan A , et al. Sonographic assessment of carpal tunnel syndrome in rheumatoid arthritis: prevalence and correlation with disease activity. Rheumatol Int 2012; 32 (8) 2313-2319
• 80 Balagtas-Balmaseda OM, Grabois M, Balmaseda PF, Lidsky MD. Cubital tunnel syndrome in rheumatoid arthritis. Arch Phys Med Rehabil 1983; 64 (4) 163-166
• 81 Malipeddi A, Reddy VR, Kallarackal G. Posterior interosseous nerve palsy: an unusual complication of rheumatoid arthritis: case report and review of the literature. Semin Arthritis Rheum 2011; 40 (6) 576-579
• 82 Birnbaum J, Bingham III CO. Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors. Semin Arthritis Rheum 2014; 43 (5) 638-647
• 83 Crispín JC, Liossis SN, Kis-Toth K , et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16 (2) 47-57
• 84 Brey RL, Holliday SL, Saklad AR , et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58 (8) 1214-1220
• 85 Huynh C, Ho SL, Fong KY, Cheung RT, Mok CC, Lau CS. Peripheral neuropathy in systemic lupus erythematosus. J Clin Neurophysiol 1999; 16 (2) 164-168
• 86 Omdal R, Mellgren SI, Husby G, Salvesen R, Henriksen OA, Torbergsen T. A controlled study of peripheral neuropathy in systemic lupus erythematosus. Acta Neurol Scand 1993; 88 (1) 41-46
• 87 Oomatia A, Fang H, Petri M, Birnbaum J. Peripheral neuropathies in systemic lupus erythematosus (SLE): clinical features, disease associations, and immunological characteristics evaluated over a 25-year study period. Arthritis Rheum 2013; ; [Epub ahead of print]
• 88 Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 2011; 41 (2) 203-211
• 89 Santiago-Casas Y, Peredo RA, Vilá LM. Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barre syndrome-like acute axonal neuropathies: report of two cases. Lupus 2013; 22 (3) 324-327
• 90 Anyfantakis D, Symvoulakis EK, Barbounakis E , et al. A fatal case of seronegative, late-onset systemic lupus erythematosus presenting with motor sensory axonal polyneuropathy. Mod Rheumatol 2014; ; [Epub ahead of print]
• 91 Ubogu EE, Zaidat OO, Suarez JI. Acute motor-sensory axonal neuropathy associated with active systemic lupus erythematosus and anticardiolipin antibodies. J Clin Rheumatol 2001; 7 (5) 326-331
• 92 Hoyle C, Ewing DJ, Parker AC. Acute autonomic neuropathy in association with systemic lupus erythematosus. Ann Rheum Dis 1985; 44 (6) 420-424
• 93 Labrador-Horrillo M, Martinez-Valle F, Gallardo E, Rojas-Garcia R, Ordi-Ros J, Vilardell M. Anti-ganglioside antibodies in patients with systemic lupus erythematosus and neurological manifestations. Lupus 2012; 21 (6) 611-615
• 94 Erkan D, Merrill JT. Severe Guillain-Barre-like peripheral neuropathy in a patient with systemic lupus erythematosus: recovery after two separate accidental burn injuries. J Clin Rheumatol 2000; 6 (5) 278-282
• 95 McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol 1998; 55 (12) 1513-1520
• 96 Smith AG, Howard JR, Kroll R , et al. The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. J Neurol Sci 2005; 228 (1) 65-69
• 97 Mawrin C, Brunn A, Röcken C, Schröder JM. Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol 2003; 105 (4) 365-372
• 98 Straub RH, Zeuner M, Lock G , et al. Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis. J Rheumatol 1996; 23 (1) 87-92
• 99 Straub RH, Glück T, Zeuner M, Schölmerich J, Lang B. Association of pupillary parasympathetic hyperreflexia and systemic inflammation in patients with systemic lupus erythematosus. Br J Rheumatol 1998; 37 (6) 665-670
• 100 Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358 (9) 929-939
• 101 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40 (9) 1725
• 102 Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L , et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64 (4) 620-625
• 103 Jamilloux Y, Magy L, Hurtevent JF , et al. Immunological profiles determine neurological involvement in Sjögren's syndrome. Eur J Intern Med 2014; 25 (2) 177-181
• 104 Gøransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, Omdal R. Peripheral neuropathy in primary Sjogren syndrome: a population-based study. Arch Neurol 2006; 63 (11) 1612-1615
• 105 Mori K, Iijima M, Koike H , et al. The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain 2005; 128 (Pt 11) 2518-2534
• 106 Sène D, Cacoub P, Authier FJ , et al. Sjögren syndrome-associated small fiber neuropathy: characterization from a prospective series of 40 cases. Medicine (Baltimore) 2013; ; Epub ahead of print
• 107 Sène D, Jallouli M, Lefaucheur JP , et al. Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) 2011; 90 (2) 133-138
• 108 Teixeira F, Moreira I, Silva AM, Vasconcelos C, Farinha F, Santos E. Neurological involvement in Primary Sjögren syndrome. Acta Reumatol Port 2013; 38 (1) 29-36
• 109 Flanagan EP, Kaufmann TJ, Keegan BM. Sjogren's syndrome with trigeminal neuropathy: motor involvement. Pract Neurol 2013; 13 (5) 340-342
• 110 Pavlakis PP, Alexopoulos H, Kosmidis ML , et al. Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012; 39 (1-2) 27-33
• 111 Grant IA, Hunder GG, Homburger HA, Dyck PJ. Peripheral neuropathy associated with sicca complex. Neurology 1997; 48 (4) 855-862
• 112 Pittock SJ, Lennon VA, de Seze J , et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65 (1) 78-83
• 113 Kim SM, Waters P, Vincent A , et al. Sjogren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009; 15 (9) 1062-1068
• 114 Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35 (1) 66-69
• 115 Dyck PJ, Hunder GG, Dyck PJ. A case-control and nerve biopsy study of CREST multiple mononeuropathy. Neurology 1997; 49 (6) 1641-1645
• 116 Knupp-Oliveira S, Cerinic MM. Polyneuropathy as initial manifestation of systemic sclerosis (scleroderma). Scand J Rheumatol 1999; 28 (4) 260-261
• 117 Frech TM, Smith G, Reily M , et al. Peripheral neuropathy: a complication of systemic sclerosis. Clin Rheumatol 2013; 32 (6) 885-888
• 118 Di Trapani G, Tulli A, La Cara A, Laurienzo P, Mazza S, David P. Peripheral neuropathy in course of progressive systemic sclerosis. Light and ultrastructural study. Acta Neuropathol 1986; 72 (2) 103-110
• 119 Reveille JD, Solomon DH ; American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49 (3) 399-412
• 120 Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6 (2) 112-116
• 121 Marsh MN. The natural history of gluten sensitivity: defining, refining and re-defining. QJM 1995; 88 (1) 9-13
• 122 Bodd M, Tollefsen S, Bergseng E, Lundin KE, Sollid LM. Evidence that HLA-DQ9 confers risk to celiac disease by presence of DQ9-restricted gluten-specific T cells. Hum Immunol 2012; 73 (4) 376-381
• 123 Asquith P, Thompson RA, Cooke WT. Serum-immunoglobulins in adult coeliac disease. Lancet 1969; 2 (7612) 129-131
• 124 Cornell HJ. Circulating antibodies to wheat gliadin fractions in coeliac disease. Arch Dis Child 1974; 49 (6) 454-458
• 125 Ruuskanen A, Luostarinen L, Collin P , et al. Persistently positive gliadin antibodies without transglutaminase antibodies in the elderly: gluten intolerance beyond coeliac disease. Dig Liver Dis 2011; 43 (10) 772-778
• 126 Hadjivassiliou M, Grünewald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry 2002; 72 (5) 560-563
• 127 Cooke WT, Smith WT. Neurological disorders associated with adult coeliac disease. Brain 1966; 89 (4) 683-722
• 128 Leeds JS, Hopper AD, Hadjivassiliou M, Tesfaye S, Sanders DS. High prevalence of microvascular complications in adults with type 1 diabetes and newly diagnosed celiac disease. Diabetes Care 2011; 34 (10) 2158-2163
• 129 Hadjivassiliou M, Rao DG, Wharton SB, Sanders DS, Grünewald RA, Davies-Jones AG. Sensory ganglionopathy due to gluten sensitivity. Neurology 2010; 75 (11) 1003-1008
• 130 Hadjivassiliou M, Grünewald RA, Kandler RH , et al. Neuropathy associated with gluten sensitivity. J Neurol Neurosurg Psychiatry 2006; 77 (11) 1262-1266
• 131 Hernandez L, Green PH. Extraintestinal manifestations of celiac disease. Curr Gastroenterol Rep 2006; 8 (5) 383-389
• 132 Hadjivassiliou M, Duker AP, Sanders DS. Gluten-related neurologic dysfunction. Handb Clin Neurol 2014; 120: 607-619
• 133 Green PH. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology 2005; 128 (4) (Suppl. 01) S74-S78
• 134 Luostarinen L, Pirttilä T, Collin P. Coeliac disease presenting with neurological disorders. Eur Neurol 1999; 42 (3) 132-135
• 135 Chin RL, Sander HW, Brannagan TH , et al. Celiac neuropathy. Neurology 2003; 60 (10) 1581-1585
• 136 Bürk K, Farecki ML, Lamprecht G , et al. Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord 2009; 24 (16) 2358-2362
• 137 Chin RL, Latov N, Green PH, Brannagan III TH, Alaedini A, Sander HW. Neurologic complications of celiac disease. J Clin Neuromuscul Dis 2004; 5 (3) 129-137
• 138 Barbato M, Curione M, Amato S , et al. Autonomic imbalance in celiac children. Minerva Pediatr 2010; 62 (4) 333-338
• 139 Usai P, Usai Satta P, Savarino V, Boy MF. Autonomic neuropathy in adult celiac disease. Am J Gastroenterol 1996; 91 (8) 1676-1677
• 140 Gibbons CH, Freeman R. Autonomic neuropathy and coeliac disease. J Neurol Neurosurg Psychiatry 2005; 76 (4) 579-581
• 141 Cicarelli G, Della Rocca G, Amboni M , et al. Clinical and neurological abnormalities in adult celiac disease. Neurol Sci 2003; 24 (5) 311-317
• 142 Brannagan III TH, Hays AP, Chin SS , et al. Small-fiber neuropathy/neuronopathy associated with celiac disease: skin biopsy findings. Arch Neurol 2005; 62 (10) 1574-1578
• 143 Anandacoomaraswamy D, Ullal J, Vinik AI. A 70-year-old male with peripheral neuropathy, ataxia and antigliadin antibodies shows improvement in neuropathy, but not ataxia, after intravenous immunoglobulin and gluten-free diet. J Multidiscip Healthc 2008; 1: 93-96
• 144 Rigamonti A, Magi S, Venturini E, Morandi L, Ciano C, Lauria G. Celiac disease presenting with motor neuropathy: effect of gluten free-diet. Muscle Nerve 2007; 35 (5) 675-677
• 145 Kaplan JG, Pack D, Horoupian D, DeSouza T, Brin M, Schaumburg H. Distal axonopathy associated with chronic gluten enteropathy: a treatable disorder. Neurology 1988; 38 (4) 642-645
• 146 Chin RL, Tseng VG, Green PH, Sander HW, Brannagan III TH, Latov N. Multifocal axonal polyneuropathy in celiac disease. Neurology 2006; 66 (12) 1923-1925
• 147 Briani C, Zara G, Alaedini A , et al. Neurological complications of celiac disease and autoimmune mechanisms: a prospective study. J Neuroimmunol 2008; 195 (1-2) 171-175
• 148 Rashtak S, Rashtak S, Snyder MR , et al. Serology of celiac disease in gluten-sensitive ataxia or neuropathy: role of deamidated gliadin antibody. J Neuroimmunol 2011; 230 (1-2) 130-134
• 149 Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D. Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol 2008; 64 (3) 332-343
• 150 Hadjivassiliou M, Aeschlimann P, Sanders DS , et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology 2013; 80 (19) 1740-1745
• 151 Hadjivassiliou M, Kandler RH, Chattopadhyay AK , et al. Dietary treatment of gluten neuropathy. Muscle Nerve 2006; 34 (6) 762-766
• 152 Luostarinen L, Himanen SL, Luostarinen M, Collin P, Pirttilä T. Neuromuscular and sensory disturbances in patients with well treated coeliac disease. J Neurol Neurosurg Psychiatry 2003; 74 (4) 490-494
• 153 Sander HW, Magda P, Chin RL , et al. Cerebellar ataxia and coeliac disease. Lancet 2003; 362 (9395) 1548
• 154 Bennett R, Friend R, Marcus D , et al. Criteria for the diagnosis of fibromyalgia: validation of the modified 2010 preliminary ACR criteria and the development of alternative criteria. Arthritis Care Res (Hoboken) 2014; ; epub ahead of print
• 155 Vargas-Alarcon G, Alvarez-Leon E, Fragoso JM , et al. A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia. BMC Musculoskelet Disord 2012; 13: 23
• 156 Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013; 154 (11) 2310-2316
• 157 Üçeyler N, Zeller D, Kahn AK , et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain 2013; 136 (Pt 6) 1857-1867
• 158 Giannoccaro MP, Donadio V, Incensi A, Avoni P, Liguori R. Small nerve fiber involvement in patients referred for fibromyalgia. Muscle Nerve 2014; 49 (5) 757-759
• 159 Klauenberg S, Maier C, Assion HJ , et al. Depression and changed pain perception: hints for a central disinhibition mechanism. Pain 2008; 140 (2) 332-343
• 160 Üçeyler N, Sommer C. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013; 154 (11) 2569
• 161 Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012; 12: CD008242
• 162 Wright A, Luedtke KE, Vandenberg C. Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy. J Pain Res 2011; 4: 1-10
• 163 Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; (3) CD007938
• 164 Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; (10) CD009183
• 165 Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012; 2: CD009318